AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00951288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron
Description: Saffron 20 mg/day supplementation
Study NCT00951288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00755196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728
Description: AN2728 Ointment, 5%, twice daily for 12 weeks
Study NCT00755196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle
Description: Ointment vehicle, twice daily for 12 weeks
Study NCT03840057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Injection
Description: Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
Study NCT03840057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Injectable Solution
Description: Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
Study NCT03840057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Normal saline is used as a placebo control.
Study NCT01406795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore Viabahn Heparin Coated Stent
Description: For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
Study NCT05618470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wumeiwan Jiawei Fang
Description: orally administered Wumeiwan Jiawei Fang prescription granules, 1 dose a day, twice a day, once for 14 days, for 42 days.
Study NCT05618470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: Botulinum toxin (Lanzhou Biopharmaceutical Co., LTD.) was injected into the medial side of the upper eyelid, the lateral side of the upper eyelid, the lateral side of the lower eyelid, and the temporal orbicularis oculi muscle of the lateral canthus. The botulinum toxin type A was diluted into 50IU/ML with normal saline and injected with a 1ml skin test syringe (4\\ 5-gauge needle), and 2.5IU was injected into each point. A total of 1 injection.
Study NCT03830164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Given PO
Study NCT03830164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Given PO
Study NCT03830164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E Compound
Description: Given PO
Study NCT01208012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza®
Description: Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
Study NCT05360316 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ESWT
Description: extracorporeal shock wave therapy
Study NCT00503152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study NCT00503152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study NCT00503152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/Valsartan
Description: After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
Study NCT02835482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtolaser surgery
Study NCT02835482 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femtolaser surgery
Study NCT02835482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Study NCT02835482 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phacoemulsification
Study NCT03920657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Fixed dose of 3.5 mg/kg/day of DFX FCT
Study NCT00305045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain structures.
Study NCT00305045 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Magnetic pulses to specified brain structures.
Study NCT04339465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-FAM
Description: CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months.
Study NCT04339465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEP-CARE
Description: WEP-CARE is an online-intervention that addresses parents of children and adolescents affected by rare diseases. The program is based on principles of cognitive-behavioral writing therapy. Supported by trained professionals, the participants perform 12 standardized writing tasks on a secured internet platform
Study NCT01675557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: a single oral dose of vitamin D3
Study NCT01675557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: a single oral dose of vitamin D2
Study NCT01675557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single oral dose of placebo
Study NCT02541526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
Study NCT02541526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
Study NCT00957814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Systematic nutritional orientation program
Study NCT02300090 — intervention group
Intervention type: DEVICE
Intervention: Test Group
Description: Patients receive a mobile phone with the Me \& My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
Study NCT02300090 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: Patients in the control group receive only standard care; there are no interventions within this group of patients
Study NCT03205553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SoC Staged Silo Closure
Description: Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.
Study NCT03205553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SoC Staged Silo Closure
Description: Serial reductions will be performed with silastic silo placement for staged reduction using umbilical tape ties. The silo is assessed daily on morning rounds by the surgical team. Once the abdominal contents are at the level of the fascia, the abdomen is closed in the operating room. The average day to closure historically from CHND data is 5 days.
Study NCT03205553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis Solution/Dextrose 1.5%
Description: Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
Study NCT02848326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant capsule.
Study NCT02848326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Atogepant
Description: Placebo-matching atogepant capsule.
Study NCT02848326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Atogepant
Description: Placebo-matching atogepant capsule.
Study NCT01313416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-011
Description: 3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
Study NCT01313416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m\^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
Study NCT00637390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
Study NCT03677648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
Study NCT03677648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
Study NCT03677648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
Study NCT03677648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos
Study NCT02999178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study NCT02999178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00192608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir 500 formulation
Description: NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
Study NCT00192608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cross-over arm
Description: either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
Study NCT03150602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
Study NCT00762086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AngioPress Intermittent pneumatic compression (IPC) Device
Description: Treatment with Intermittent pneumatic compression (IPC) for PAD
Study NCT00762086 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medications and Standard walking exercises
Description: Aspirin/Clopidegrol and Standard walking exercises
Study NCT04123210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A supplement
Study NCT04123210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03940001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Other Name: (IBI308)
Study NCT03940001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/paclitaxel
Description: carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
Study NCT03940001 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: IMRT or VMAT
Study NCT03597490 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Multimodal physical therapy with exercise
Description: Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
Study NCT04028453 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation survey.
Study NCT05901948 — intervention group
Intervention type: OTHER
Intervention: Classification
Description: Novel Asherman Scoring Classification
Study NCT03500861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
Study NCT03500861 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dry Needling
Description: The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
Study NCT00301756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Given IV
Study NCT00301756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01642511 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc-labeled Sulfur Colloid
Description: Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5\~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
Study NCT01642511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Sentinel Lymph Node Biopsy
Description: Sentinel lymph node biopsy
Study NCT01642511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Sentinel Lymph Node Biopsy
Description: Sentinel lymph node biopsy
Study NCT01642511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylthioninium
Description: Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
Study NCT01642511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylthioninium
Description: Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
Study NCT01642511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoscintigraphy
Description: Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
Study NCT01642511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Description: Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
Study NCT01642511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection
Description: ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
Study NCT01642511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
Study NCT01642511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Mammary Sentinel Lymph Node Biopsy
Description: Internal mammary sentinel lymph node biopsy
Study NCT01642511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Mammary Sentinel Lymph Node Biopsy
Description: Internal mammary sentinel lymph node biopsy
Study NCT02969837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
Study NCT02969837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
Study NCT02969837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be given on days 1-21 for all cycles.